Stopping anti-TNF in CD remitters: pros and cons
Background: There is no cure for Crohn’s disease. Available treatments and treatment strategies, particularly anti-TNF, allow to heal intestinal lesions and maintain steroid-free remission in a subset of patients. Having in mind the remitting/relapsing nature of the disease, patients and health care...
Guardado en:
Autor principal: | Edouard Louis |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Karger Publishers
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/9c7c589f733a4b9e9e8123a4e50722c4 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Clinical approach to skin eruptions induced by anti-TNF agents among patients with inflammatory bowel diseases: insights from a multidisciplinary IBD-DERMA clinic
por: Henit Yanai, et al.
Publicado: (2021) -
Serum anti-modified citrullinated vimentin antibody concentration is associated with liver fibrosis in patients with chronic hepatitis
por: Suad Abdeen, et al.
Publicado: (2011) -
Should NS5A inhibitors serve as the scaffold for all-oral anti-HCV combination therapies?
por: Janardhan SV, et al.
Publicado: (2015) -
Impact of medical therapies for inflammatory bowel disease on the severity of COVID-19: a systematic review and meta-analysis
por: Mohammad Shehab, et al.
Publicado: (2021) -
Impact of early cholecystectomy on the readmission rate in patients with acute gallstone cholangitis: a retrospective single-centre study
por: Bishnu Sapkota, et al.
Publicado: (2021)